Larazotide Dosage, half-life & reference guide
Also known as AT-1001 · Larazotide Acetate
An oral drug candidate aimed at the 'gates' between cells in your gut lining: it blocks the zonulin pathway to keep them closed.
- Studied range
- 0.5–1 mg
- How often
- 3× daily
- Half-life
- Very short
- Evidence
- ●●
●Moderate - Route
- Oral
Studied in research — not a recommendation.
How it works.
Tight junction regulator that blocks the zonulin pathway to reduce gut permeability; in cell and animal studies it tightens the junctions between gut cells. In human celiac trials the gut-permeability test didn't change. Phase 2 trials were run in celiac disease, and a phase 3 was stopped in 2022 after an interim analysis.
Commonly reported: Less bloating and post-meal discomfort, though many notice little. It reached phase 3 trials in celiac disease but was never approved.
Where Larazotide works.
Gut
In people. In the 12-week celiac trial, the lowest dose eased gut symptoms along with headache and tiredness.
An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.
Week by week.
What to expect in the first 8 weeks
Day 1–14RCT
Early days at the gut lining
Larazotide acts right where it's swallowed, at the gut lining, and it's designed to keep the gaps between gut cells closed. Commonly reported in the first two weeks, by those who notice a change: less bloating and discomfort after meals.
The science
Larazotide blocks zonulin-mediated tight junction opening. Unlike systemic peptides, it's a local-acting drug — minimal absorption, action confined to the intestinal epithelium. Phase 2b celiac trial data (Leffler et al. 2015) showed symptom reduction starting within the first 2 weeks.
Sources- Leffler et al. (2015)
Updated Apr 2026
Day 14–42RCT
What users notice in weeks 2 to 6
Commonly reported in weeks 2 to 6: steadier digestion, and for some less tiredness and fewer headaches. In the 12-week celiac trial, the lowest dose eased gut symptoms along with headache and tiredness.
The science
Less leakage between gut cells means less LPS and food-peptide exposure for the immune tissue underneath. In the 12-week phase 2b (Leffler 2015), the symptom benefit at 0.5 mg held through week 12; the 1 mg and 2 mg doses didn't beat placebo, and the gut-permeability test didn't change in these trials (Kelly 2013).
Sources- Leffler et al. (2015)
- Kelly et al. (2013)
Updated Apr 2026
Day 42–84Community
Taper or maintain
By now most users know whether it helps: steadier symptoms, easier meals. This is when many taper, or keep a lower dose alongside diet and BPC-157.
The science
The phase 3 (CeD-LA-3001) was stopped in June 2022 after an interim analysis found it couldn't show a benefit without far more patients, so long-term clinical data are limited. In lab studies it remains one of the best-characterized tight-junction modulators.
Sources- NCT03569007 (2022)
Updated Sep 2026
Any dayRCT
What Larazotide is built on
Larazotide has more human trial data than any other gut-barrier peptide: phase 2 celiac trials with mixed results and a phase 3 that was stopped in 2022, so it was never approved. Its safety record in those trials was good.
The science
In the 342-patient phase 2b, only the lowest dose (0.5 mg) met the primary symptom endpoint (Leffler 2015); a gluten-challenge trial missed its permeability endpoint (Kelly 2013). 9 Meters Biopharma ran the phase 3 (CeD-LA-3001) in celiac patients with persistent symptoms on a gluten-free diet and stopped it in June 2022 after an interim analysis. No systemic toxicity in any trial, as absorption is minimal.
Sources- Leffler et al. (2015)
- Kelly et al. (2013)
- NCT03569007 (2022)
Updated Sep 2026
With BPC-157 and KPVCommunity
Gut repair trio
Three layers of the same problem: larazotide targets the gaps between gut cells, BPC-157 supports deeper repair of the gut lining, and KPV damps the inflammation in between. A common practitioner stack for gut recovery. Commonly reported: calmer digestion over several weeks.
The science
Three mechanisms, three compartments: tight junction (larazotide), mucosal regeneration (BPC-157, animal studies), inflammatory signaling (KPV, cell and mouse studies). No study has tested the combination; the logic comes from functional GI practice.
Sources- Sikiric et al. (2018)
Updated Sep 2026
Day 1 is the day you start it.
A typical run.
Run notes
- Cycle
- Typically used for 4–12 weeks alongside gut healing protocols.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- 3x daily with meals for targeted gut barrier effect.
- Route
- Oral
- Stacks
- BPC-157, KPV
Safety.
Common side effects
- Generally well tolerated
- Mild GI upset
- Nausea
Questions people ask.
What is Larazotide?
An oral drug candidate aimed at the 'gates' between cells in your gut lining: it blocks the zonulin pathway to keep them closed.
How is Larazotide dosed in research?
The research range for Larazotide is 0.5–1 mg, 3x daily with meals. Studied in research — not a recommendation.
How long does Larazotide last?
The half-life of Larazotide is very short (local gut action).
What do people report on Larazotide?
Commonly reported on Larazotide: less bloating and post-meal discomfort, though many notice little. It reached phase 3 trials in celiac disease but was never approved.
Is Larazotide safe?
The research basis for Larazotide is moderate: animal studies + some human data. Common side effects in the library: generally well tolerated, mild GI upset and nausea.
What does Larazotide stack with?
Common stacks for Larazotide: BPC-157 and KPV.
Research.
Reference.
- Cadence
3× daily
3x daily with meals
- Half-life
Very short
Very short (local gut action)
- Research basis
●●
●ModerateAnimal studies + some human data
PepVault for iPhone
Track Larazotide in PepVault
Log every dose, with reminders on your schedule. 7 days free on the yearly plan for new subscribers.
Reviewed How we check the library